Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Privium Fund Management B.V.

Privium Fund Management B.V. lowered its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 16.0% in the fourth quarter, HoldingsChannel reports. The fund owned 398,204 shares of the biotechnology company’s stock after selling 75,747 shares during the quarter. Arrowhead Pharmaceuticals makes up about 4.9% of Privium Fund Management B.V.’s portfolio, making the stock its 6th largest position. Privium Fund Management B.V.’s holdings in Arrowhead Pharmaceuticals were worth $26,437,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. CWM LLC increased its stake in shares of Arrowhead Pharmaceuticals by 1.4% during the 4th quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock valued at $820,000 after acquiring an additional 168 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 3.1% during the 3rd quarter. PNC Financial Services Group Inc. now owns 10,924 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 326 shares during the last quarter. WPG Advisers LLC increased its stake in shares of Arrowhead Pharmaceuticals by 384.8% during the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 431 shares during the last quarter. First Horizon Corp acquired a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $32,000. Finally, State of Wyoming increased its stake in shares of Arrowhead Pharmaceuticals by 5.6% during the 3rd quarter. State of Wyoming now owns 9,519 shares of the biotechnology company’s stock valued at $328,000 after acquiring an additional 504 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on ARWR shares. Piper Sandler reissued an “overweight” rating and set a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $78.00 to $100.00 in a research report on Tuesday, April 21st. The Goldman Sachs Group increased their target price on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. Weiss Ratings raised shares of Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. Finally, Chardan Capital increased their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $84.20.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, CFO Daniel Joseph Apel sold 13,095 shares of the company’s stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the transaction, the chief financial officer owned 162,905 shares in the company, valued at $11,623,271.75. This represents a 7.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the transaction, the insider owned 226,958 shares of the company’s stock, valued at approximately $17,021,850. This represents a 4.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 33,095 shares of company stock valued at $2,326,228. 3.60% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Stock Down 1.9%

ARWR opened at $74.93 on Wednesday. The firm has a 50 day moving average price of $63.70 and a 200 day moving average price of $59.78. The company has a market cap of $10.49 billion, a PE ratio of 48.97 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $12.44 and a 1 year high of $77.90. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The company had revenue of $264.03 million during the quarter, compared to analysts’ expectations of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm’s revenue was up 10461.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.39) EPS. Sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.37 earnings per share for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.